TL;DR
Researchers have identified a novel synthetic lethal interaction in Acute Myeloid Leukemia (AML) cells that overexpress the PRL-3 phosphatase. By simultaneously inhibiting the AKT/mTOR and WNT/β-catenin signaling pathways, they achieved significant synergistic killing of these cancer cells, offering a promising new therapeutic strategy for a subset of AML patients with poor prognoses.
What Problem Does This Paper Address?
Acute Myeloid Leukemia (AML) is a diverse and aggressive blood cancer with a challenging 5-year survival rate. While protein tyrosine phosphatase of regenerating liver 3 (PRL-3) is known to be overexpressed in a significant portion of AML patients, particularly those with a worse prognosis, developing a direct inhibitor for PRL-3 has been difficult due to its shallow and hydrophobic active pocket. This limitation necessitates an indirect approach to target PRL-3, by identifying and exploiting pathways or molecules that cancer cells with high PRL-3 expression become dependent on for their survival. The paper aims to uncover these dependencies and explore their therapeutic potential.
Methods
The study employed a multi-pronged approach:
- Genome-wide shRNA Library Screening: A pooled, whole-genome lentiviral shRNA library was used to screen for genes that, when knocked down, were synthetically lethal to AML cells overexpressing PRL-3. This was performed using isogenic cell lines (TF1-pEGFP as control and TF1-hPRL3 with PRL-3 overexpression).
- Synthetic Lethality Validation: Small molecule inhibitors targeting the identified pathways were used to validate the synthetic lethal interactions in both cell lines and primary AML patient samples.
- Cell Viability Assays: CellTiter-Glo® Luminescent Cell Viability Assay (CTG assay) was used to measure cell growth and viability under different treatment conditions.
- Apoptosis Assays: Annexin V-FITC and propidium iodide (PI) staining followed by flow cytometry was used to quantify apoptotic cell populations.
- Western Blot Analysis: This technique was used to assess the expression levels of key proteins involved in the targeted pathways and apoptosis.
- In Vivo Xenograft Model: Human AML cells were xenografted into immunodeficient mice to evaluate the efficacy of the combination therapy in a living system, assessing survival and leukemic burden.
- Quantitative Reverse Transcription PCR (qRT-PCR): Used to confirm PRL-3 expression levels in cell lines and patient samples.
- Combination Index (CI) and Isobologram Analysis: CalcuSyn software was used to quantitatively assess the synergistic, additive, or antagonistic effects of drug combinations.
Datasets
The study utilized:
- TCGA RNA-seq data: Publicly available RNA-seq data from The Cancer Genome Atlas (TCGA) cohort was used to analyze PRL-3 gene expression and its correlation with patient survival.
- Human AML cell lines: Isogenic TF1-pEGFP and TF1-hPRL3 cell lines, along with MOLM-14 and OCI-AML2 cell lines.
- Primary AML patient samples: Bone marrow blast cells from newly diagnosed AML patients were obtained and used for validation studies.
- Mouse xenograft models: NOD/SCID mice were used to establish in vivo models of AML.
Key Insights and Ideas
- PRL-3 as a Prognostic Factor: High expression of PRL-3 is confirmed as an independent prognostic factor for poor survival in AML patients, reinforcing its therapeutic relevance.
- WNT/β-catenin and AKT/mTOR Dependency: AML cells with high PRL-3 expression exhibit a critical dependency on both the WNT/β-catenin and AKT/mTOR signaling pathways for their survival. This dependency is not as pronounced in PRL-3 low AML cells.
- Synthetic Lethality Achieved: Simultaneous inhibition of AKT/mTOR (using VS-5584) and WNT/β-catenin (using ICG-001) pathways leads to a synergistic killing effect specifically in PRL-3 high AML cells.
- Pathway Crosstalk: The findings suggest a cooperative signaling network between AKT/mTOR and WNT/β-catenin pathways that is essential for the survival of PRL-3 high AML cells.
- Targeted Therapy Potential: This combinatorial approach offers a promising strategy to selectively target and eliminate PRL-3 high AML cells, potentially sparing normal cells.
Key Results
- Genome-wide screen identified WNT/β-catenin and AKT/mTOR pathways: The shRNA screen revealed significant enrichment of genes involved in these pathways among the synthetic lethal targets of PRL-3 overexpressing cells.
- Synergistic cell death: Combination treatment with VS-5584 and ICG-001 induced significantly higher apoptosis and cell death in MOLM-14 (PRL-3 high) cells compared to single-agent treatments. This was accompanied by increased caspase 3/7 activity and PARP cleavage.
- PRL-3 level dictates synergy: The synergistic effect of the combination therapy was strongly associated with the level of PRL-3 expression. Primary AML samples with high PRL-3 showed synergistic killing, while those with low PRL-3 exhibited additive or antagonistic effects.
- Improved survival in vivo: In AML xenograft mouse models, the combination therapy significantly prolonged survival and reduced leukemic burden in mice engrafted with PRL-3 high AML cells (MOLM-14) compared to single-agent treatments or vehicle control. This effect was not observed in mice engrafted with PRL-3 low AML cells (OCI-AML2).
Limitations and Future Work
- Potential for shRNA pool representation issues: The authors acknowledge that using only a portion of DNA extracted from each shRNA pool for PCR and sequencing might pose challenges in representing the entire shRNA pool.
- In vitro vs. in vivo differences: While the in vitro results were largely recapitulated in vivo, further validation in more complex models might be beneficial.
- Broader applicability: The authors suggest that this combination therapy might be effective in other cancers that express high levels of PRL-3, but this requires further investigation.
- Clinical Translation: The study strongly warrants further clinical investigation to evaluate the efficacy and safety of this combinatorial therapy in AML patients with high PRL-3 expression.
Summary updated